Startups

ONWARD Medical

Eindhoven, Netherlands

Public medical-device company ONWARD Medical N.V. (Euronext ONWD), developing spinal-cord stimulation and ARC therapies. ARC-EX approvals differ from investigational ARC-IM and ARC-BCI. Lausanne is an office/scientific origin, not current sole HQ; unrelated to Onward fintech.

Founded 2015

Team

Alexandre CasteauHead strategy and corporate development

Ali KiboroCFO, joined January 2026

Amori Frasersenior finance director

Bob OdellVP operations

Dave MarverCEO

Grégoire CourtineScientific founder / advisor

Jocelyne BlochScientific co-founder / medical advisor

Julie CromDirector people and culture

Julien CamisaniVP engineering

Lorenzo FantiVP legal

Sean Sciarachief commercial officer

Shari O’Quinnchief clinical, regulatory and quality officer

Sébastien CrosVP communications

Investments

€40M2026-04-16	EQT Life Sciences
€50M2025-10-24	Ottobock, The Invus Group, LLC, ASR Global Impact Equity Fund
€50M2024-10-24	Ottobock
$17M2024-06-28	Runway Growth Finance Corp.
$32M2021-04-22	INKEF Capital
$—Unknown date	SCI Ventures

team@apexlogos.aiyesterday
RELATED
team@apexlogos.aiyesterday
BCI research snapshot, reviewed 2026-10-06. Company identity: ONWARDMedical. This is the pre-import evidence dossier; historical statements about database absence or review are archival. Unverified claims remain research leads, not validated facts. Part 1/1 # ONWARD Medical Accessed: 2026-10-06. Research report for human review; no database changes made. Direct image URLs are extracted source assets, not invented filenames. Funding ledger is verified events found, not a complete lifetime total. ## Identity and pasted claims [ONWARD Medical N.V.](https://ir.onwd.com/) is a Netherlands public medical-device company (Euronext ONWD), founded in 2015. Current investor site states headquarters Eindhoven, Netherlands; Lausanne is an office and scientific origin, Boston a US location. Thus pasted Lausanne-only HQ needs correction. Dave (David) Marver remains CEO. Scientific founders Grégoire Courtine and Jocelyne Bloch are identified in the [2024 company transcript](https://ir.onwd.com/static-files/7c85f572-283d-44c6-82d7-20d0b823cca1). ARC-EX is external spinal-cord stimulation with US clinic/home and European commercial approvals; ARC-IM implantable therapy remains clinical/investigational and ARC-BCI pairs stimulation with implanted brain signals. An active public company is validated. Do not label all ARC products approved. Current product and business status: [September 2026 company results](https://www.globenewswire.com/news-release/2026/09/09/3358303/0/en/onward-medical-reports-first-half-2026-results-with-strong-product-revenue-growth-and-continued-progress-across-arc-therapy-pipeline.html). ## Logo and public team Company icon: https://www.onwd.com/wp-content/uploads/2023/10/onward-favicon.svg — actual favicon link extracted from onwd.com HTML. The main logo is inline SVG, so this is an icon alternative, not a portrait. Current roles and images from [official investor team](https://ir.onwd.com/). Portraits were mapped to named adjacent cards in [official main about-page HTML](https://www.onwd.com/about/), independently extracted by root reviewer. These replace blocked encrypted IR assets. | Person | Role / currency | Profile and evidence | Direct pfp URL | |---|---|---|---| | Dave Marver | Current CEO | [Current official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2024/09/Dave2.jpg | | Ali Kiboro | Current CFO, joined January 2026 | [Current official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2026/01/Ali-Kiboro.png | | Sean Sciara | Current chief commercial officer | [Current official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2025/06/OWRD-1-SS.jpg | | Shari O’Quinn | Current chief clinical, regulatory and quality officer | [Current official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2025/12/Photo_S-OQuinn-2025-12-Copy.jpg | | Amori Fraser | Current senior finance director | [Current official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2024/08/Amori.jpg | | Julien Camisani | Current VP engineering | [Current official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2024/08/Julien.jpg | | Bob Odell | Current VP operations | [Current official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2024/08/Bob.jpg | | Grégoire Courtine | Scientific founder; scientific advisor; left board July2025 | [Company board notice](https://ir.onwd.com/static-files/6f497f03-67ff-407c-b5a6-5144cd982f95) | Unavailable from consulted founder sources. | | Jocelyne Bloch | Scientific co-founder / medical advisor | [Company transcript](https://ir.onwd.com/static-files/7c85f572-283d-44c6-82d7-20d0b823cca1) | Unavailable from consulted founder sources. | | Sébastien Cros | Current VP communications | [Official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2025/06/OWRD-2-SC.jpg | | Alexandre Casteau | Current Head strategy and corporate development | [Official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2024/09/Alex-C-headshot.jpg | | Julie Crom | Current Director people and culture | [Official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2024/08/Julie.jpg | | Lorenzo Fanti | Current VP legal | [Official team](https://www.onwd.com/about/) | https://www.onwd.com/wp-content/uploads/2024/08/larenzo.jpg | ## Financing ledger | Date | Amount | Type | Named investors / distinction | Evidence | |---|---|---|---|---| | 2024-10-24 | EUR50M | Public equity private placement | Ottobock EUR22.5M is included, not additional | [Euronext issuer release](https://live.euronext.com/en/products/equities/company-news/2024-10-24-onwardr-medical-successfully-raises-eur-50-million) | | 2025-10-24 | EUR50.85M | Public equity capital increase | Ottobock cornerstone, Invus, ASR Global Impact Equity Fund; 11.3M shares ×EUR4.50. Release typo “million” after full euro amount should not be imported | [Issuer release](https://www.globenewswire.com/news-release/2025/10/24/3172595/0/en/onward-medical-successfully-raises-over-eur-50-million-in-capital-increase.html) | | 2026-04-16 | EUR40.6M | Public equity capital increase | EQT Life Sciences EUR25M included in total | [Issuer release](https://www.globenewswire.com/news-release/2026/04/16/3275024/0/en/ONWARD-Medical-Successfully-Raises-over-EUR-40-Million-in-Capital-Increase.html) | | 2026-09-09 results | Up to EUR50M; EUR20M drawn at closing | Debt / refinancing | BlackRock; replaces Runway Growth Capital facility, not a venture round | [Company H1results](https://www.globenewswire.com/news-release/2026/09/09/3358303/0/en/onward-medical-reports-first-half-2026-results-with-strong-product-revenue-growth-and-continued-progress-across-arc-therapy-pipeline.html) | This is a partial verified ledger, not all pre-IPO financing or IPO events. Pasted CHF100M+ is not a sourced lifetime total and combines currencies without a stated conversion date. Grant income and product sales must not be modeled as investments. ## Review / import decision Create distinct `OnwardMedical`. Existing `Onward` is a co-parent fintech entity and must not receive these products, executives, funding or photographs. Headquarters correction and product regulatory stage are essential; complete missing photos and historical financing before importing a lifetime total.